Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model

Bernice Nounamo,1 Jason Liem,1 Martin Cannon,1 and Jia Liu1,2

A therapeutic approach to improve treatment outcome of ovarian cancer (OC) in patients is urgently needed. Myxoma virus (MYXV) is a candidate oncolytic virus that infects to eliminate OC cells. We found that in vitro MYXV treatment enhances cisplatin or gemcitabine treatment by allowing lower doses than the corresponding IC50 calculated for primary OC cells. MYXV also affected OC patient ascites-associated CD14+ myeloid cells, one of the most abundant immunological components of the OC tumor environment; without causing cell death, MYXV infection reduces the ability of these cells to secrete cytokines such as IL-10 that are signatures of the immunosuppressive tumor environment. We found that pretreatment with replication-competent but not replication-defective MYXV-sensitized tumor cells to later cisplatin treatments to drastically improve survival in a murine syngeneic OC dissemination model. We thus conclude that infection with replication-competent MYXV before cisplatin treatment markedly enhances the therapeutic benefit of chemotherapy. Treatment with replication-competent MYXV followed by cisplatin potentiated splenocyte activation and IFNγ expression, possibly by T cells, when splenocytes from treated mice were stimulated with tumor cell antigen ex vivo. The impact on immune responses in the tumor environment may thus contribute to the enhanced antitumor activity of combinatorial MYXV-cisplatin treatment.

INTRODUCTION

Prolonging survival and preventing relapse for ovarian cancer (OC) patients remain challenging, despite the availability of appropriate surgery and highly effective first-line chemotherapy.1 It is estimated that 70% of patients with advanced OC eventually relapse in spite of remission achieved after initial treatment.1,2 Developing novel treatment approaches is urgently needed.

Immune response and especially immune status within the tumor environment play critical roles in OC progression, overall prognosis, and survival.3,4 The presence of tumor-infiltrating lymphocytes is associated with prolonged survival.3-Tumor cells, however, cultivate the tumor environment to impair antitumor immunity, an activity that has been associated with poor survival and prognosis; this immunosuppressive tumor environment is also a major obstacle for effective treatments of OC, including dendritic cell vaccination.6 Thus, an integrated treatment strategy that not only complements current chemotherapy but also alleviates immune suppression in the tumor environment could benefit the treatment of patients with OC.

Oncolytic virotherapy can be applied as a novel anticancer strategy because it not only can promote cytoreductive activity specifically against tumor cells7,8 but also stimulates the innate immunity-mediating antitumor bystander effect9 and the adaptive immune response for a prolonged therapeutic effect.10,11 The mechanism by which a long-lasting treatment benefit is triggered depends on the virus used. In general, oncolytic virotherapy has a direct cytolytic effect on cancer cells, resulting in the release of tumor antigens that leads to a cascade of events ultimately inducing antitumoral adaptive immunity. This outcome is especially valuable in the elimination of micrometastases in distant locations. Moreover, oncolytic virotherapy can facilitate the elimination of the immunosuppressive environment that protects cancer cells from systemic immune surveillance.12 The immunotherapeutic value of oncolytic virotherapy is gradually being recognized.13

The combination of oncolytic virotherapy and cytotoxic chemotherapy agents for improved treatment outcomes has been proposed.14 The synergistic effect observed through this combination treatment may be due to an escalated induction of systemic antitumor immunity.15 Myxoma virus (MYXV) is a candidate oncolytic virus on the path to clinical usage16 and possesses immunogenic properties.17,18 Although in vitro MYXV oncolytic potential has been evaluated that can effectively infect and kill patient ascites-derived OC cells grown in monolayer19 (Figures 1B and 1D), other than three-dimensional spheroids,20 it has not been investigated in the animal model.
The combination of MYXV and gemcitabine tested in a pancreatic tumor model showed a significant treatment benefit. Based on the findings in this study, the use of MYXV to treat tumor dissemination within the peritoneal space shows promise. Moreover, in the pancreatic syngeneic model tested in this earlier study, an immunosuppressive tumor environment is present, which shares similarity to the OC tumor microenvironment. Cisplatin, an alkylating agent that causes DNA damage and subsequent apoptosis, is a cisplatin to treat disseminated OC associated with an immunosuppressive tumor microenvironment. Because gemcitabine is a second-line chemotherapy option for OC, we considered it as one treatment option in our OC model as a control.

In this study, we focused on using the combination of MYXV and cisplatin to treat disseminated OC associated with an immunosuppressive tumor microenvironment. Cisplatin, an alkylating agent that causes DNA damage and subsequent apoptosis, is a first-line platinum-based chemotherapy agent against OC. Cisplatin has also been observed to impact host immune response by reducing regulatory T cells while enhancing antigen-specific CD8+ T cell activities. When cisplatin and oncolytic virotherapy are used together to achieve therapeutic benefit, however, the immunological impact differs, and specific characterization of the mechanism involved is needed.

Our study marks a first attempt to utilize MYXV and cisplatin together to treat disseminated OC in vivo. We show that combinational MYXV/cisplatin produced a significant improvement in overall survival in a mouse model of this deadly cancer.

RESULTS

MYXV Oncolytic Potential against OC Cells
We evaluated the oncolytic potential of MYXV in the established OC cell line SKOV3 and in two primary OC cell lines, OvCa-2a and OvCa-26, that were developed from patient ascites. Wild-type (WT) MYXV (vMyxGFP) could productively infect the cells, while a mutant virus lacking the replication-essential gene M062R (M062R-null MYXV or vMyxM062RKO) caused abortive infection in all OC cell lines tested (Figure 1A). Interestingly, however, infection by either mutant (M062R-null MYXV) or WT MYXV caused comparable reductions in cell viability as measured by MTT assay (Figures 1B and 1C). In patient ascites-derived OC cells, MYXV infection-associated reduction in viability is much more evident than that in the established cell line, SKOV3 (Figures 1B and 1C, respectively). Infection of SKOV3 cells with MYXV led to loss of the ability to form colonies (Figure 1D). Comparability effects by MYXV were also seen in the two primary OC cell lines (data not shown). Cell death associated with MYXV infection in the two primary OC cell lines did not show a signature of apoptosis (Figure 2). WT MYXV infection in OvCa-2a and OvCa-26 caused a moderate increase of cell death in infected cells that was not seen in replication-defective infection (GFP+; Figure 2A). On the other hand, MYXV infection of SKOV3 cells caused a slight increase in the number of cells positive for early signs of apoptosis; however, this effect was replication independent (Figure 2).

MYXV Treatment as a Complement to Chemotherapy Drugs In Vitro
We tested the sensitivity of OvCa-2a and OvCa-26 to cisplatin in comparison to SKOV3 and found OvCa-26 (calculated IC50 = 11.4 μM) to be slightly more resistant than OvCa-2a (calculated IC50 = 3.6 μM) and SKOV3 (8.4 μM). We thus focused on OvCa-26 for further testing on cisplatin response. We also found OvCa-2a (calculated IC50 = 0.96 mM) to be relatively resistant to the gemcitabine treatment compared with SKOV3 (IC50 = 9.32 μM) and OvCa-26 (14.6 μM) and chose to focus on OvCa-2a for further testing.
related to gemcitabine. At doses comparable to IC50, additive effects of drug and virus were observed in primary OC cells (Figure S1). When we treated primary OC cells with cisplatin or gemcitabine at doses much lower than their calculated IC50, we did not observe significant growth inhibition with drug treatment alone (Figure 3); the reduced cell viability in groups treated with the MYXV treatment following cisplatin or gemcitabine is caused by MYXV infection (Figures 1B and 3B). When we evaluated the effects of combinatorial treatment with MYXV followed by chemotherapy (cisplatin or gemcitabine), consistent and significant further reductions in cell viability could be detected compared with the treatment outcomes of drug first followed by MYXV (Figure 3) or MYXV alone (Figure 1B).

**MYXV Infection in OC Patient Ascites-Associated CD14+ Monocytes**

We investigated whether MYXV infection could impact the immunological properties of the OC tumor environment. We chose to examine the interaction between MYXV and OC patient ascites-associated CD14+ cells, as these cells are one of the most abundant and important players in ascites maintaining the immunosuppressive tumor environment.28 Moreover, MYXV prefers to bind and enter human CD14+ myeloid cells rather than other immune cell types29 and can activate the type I interferon (IFN) response by RIG-I in differentiated macrophages through an attachment-based induction.17 However, interestingly, MYXV infection does not cause cell death in either healthy monocytes (data not shown) or OC ascites-associated CD14+ cells (Figure 4C). We observed an unusual pattern of STAT3 phosphorylation in OC patient ascites-associated CD14+ cells with minimal phosphorylation at Y705 but a high level of phosphorylation at S727 (Figure 4A). In OC patient ascites-associated CD14+ monocytes, infection by MYXV led to reduced phosphorylation of STAT3 at serine 727 (pS727) (Figure 4B) and AKT (data not shown). The consequence of MYXV infection was a significant reduction in cytokine secretion, as shown by multiplex array (Figures 5A and 5B), which was comparable to the outcome caused by STAT3 inhibitor (Stattic) treatment (Figures 5C and 5D). Treatment of Stattic did not cause noticeable toxicity, and unchanged levels of IL-8 were detected by multiplex array (data not shown).

**MYXV Treatment in a Syngeneic Murine OC Dissemination Model**

We examined murine OC ID8 cells and found them to be sensitive to cisplatin treatment (IC50, 2.0 μM), compared to human SKOV3 cells (IC50, 8.4 μM). We evaluated MYXV as either a single agent or in combination with cisplatin in immunocompetent ID8 disseminated tumor-bearing mice.

We found that as single-agent treatment given late after tumor cell injection in the syngeneic ID8 OC model, either replication-competent
We found that the group of mice treated first with WT MYXV and then later with cisplatin remained healthy 2 months after the median survival time of the mock-treatment group (80 days), while mice in the cisplatin-alone and mock-treatment groups had all succumbed to the disease (Figure 6B). The differences are statistically significant analyzed by log rank (Mantel-Cox) test (p < 0.0001). Interestingly, although it also reached statistical significance in comparison to cisplatin-alone and mock-treatment groups (both p < 0.01), treatment first with cisplatin followed by WT MYXV (30% survival) did not provide the same benefit as MYXV pretreatment followed by cisplatin (100% survival) (Figure 6B) (p = 0.0011). More importantly, when the replication-defective mutant MYXV, vMyxM062RKo, was used for pretreatment before cisplatin (60% survival), we did not observe the same benefit conferred by WT MYXV pretreatment (Figure 6B and solid orange line in Figure 6D; 100% survival). Thus, a replication-competent MYXV is important to sensitize cancer cells to a following cisplatin treatment in order to achieve an optimal therapeutic outcome. Unexpectedly, the regime of M062R-null MYXV treatment after cisplatin (90% survival) provided a better survival outcome than cisplatin alone (40% survival) (log rank Mantel-Cox test; p = 0.0329) or mutant virus followed by cisplatin (Figure 6D) (60% survival; p = 0.1605).

We collected splenocytes from surviving mice from the following groups 100 days after tumor cell injection: cisplatin alone (early treatment group as in Figure 6B, collected after 100 days), WT MYXV alone (Figure 6B) (collected after 140 days), cisplatin plus WT MYXV (Figure 6B) (collected after 140 days), and WT MYXV plus cisplatin (Figure 6B) (collected after 140 days). After stimulation of spleen cells with ID8 tumor antigen, we examined IFNγ secretion in the supernatant as a measurement of immune cell activation. Splenocytes from the group treated with WT MYXV plus cisplatin consistently showed a strong IFNγ response (Figure 6C).

**DISCUSSION**

The oncolytic potential of MYXV is largely due to the intracellular environment of tumor cells that permits a productive MYXV infection, including highly phosphorylated AKT31 and loss of synergistic effects of the tumor necrosis factor (TNF) and IFN responses, in the transformed cells.32,33 The mechanism of oncolysis by MYXV, however, varies by the type of cancer.34,35 We found that apoptosis was not the major driver of oncolysis by MYXV in the OC cells tested, including primary OC cells derived from patient ascites. Although replication competence can moderately increase cell death, such as in WT MYXV-infected primary OC cells, the overall inhibitory effect to OC cell growth seemed to be replication independent. Further investigation on the mechanism is ongoing. More importantly, pretreatment with MYXV sensitized OC cells to much lower doses of chemotherapy agents than those given when the agents are used alone. Further investigation into the mechanism of this sensitization process is needed. It is encouraging to examine whether this treatment approach may be an alternative strategy to target chemoresistance in many OC cells, especially recurrent tumor arising after first-line chemotherapy treatment.

Within human OC ascites, CD14+ monocytes/macrophages are one of the most abundant immune cell populations.36,37 These myeloid...
cells have an M2 immunosuppressive phenotype and have been linked to resistance to platinum-based chemotherapy agents. The ability of CD14+ myeloid cells to produce IL-10 has a suppressive effect on T cells present in the OC tumor environment in the peritoneal cavity. MYXV preferentially binds and enters human CD14+ cells rather than other immune cells to initiate early gene expression without resulting in a productive infection. We found that MYXV did not affect the general viability of healthy human CD14+ cells. However, MYXV infection in OC ascites-associated CD14+ cells led to an inhibitory effect on multiple signaling pathways associated with cytokine secretion patterns that contribute to the immunosuppressive tumor environment. Thus, MYXV can be a potential immunotherapeutic tool for targeting CD14+ monocytes in the tumor environment. In the murine ID8 model of OC, we found the presence of CD11b+ cell population but few F4/80+ cells (mature macrophages) in the ascites of mice injected with this clone of ID8 cells (data not shown). It is not an optimal system to investigate the MYXV therapeutic effect against the equivalent of CD14+ cell type in human OC ascites. A recently developed model using p53 null ID8 cells with high levels of macrophages infiltration in the ascites can be a system to extend the investigation.

An initial characterization of OC patient ascites-associated CD14+ cells showed active AKT signaling and a non-canonical state of STAT3 signaling (STAT3 pY705 low/no and pS727 high). Targeting STAT3 signaling to reverse chemoresistance in OC has been suggested. However, the roles of non-canonical STAT3 signaling in OC disease progression and maintenance of immunological properties of OC are not yet characterized. Phosphorylation at serine 727 of STAT3 permits a maximal transcription activity in principle. We utilized a specific inhibitor of STAT3, Stattic, to prevent STAT3 homodimerization and DNA binding and observed suppressive effect in cytokine secretion of tumor-associated CD14+ macrophages (Figure 5, control). Our results showed that MYXV infection could suppress STAT3 (STAT3 pY705 low/no and pS727 high) and AKT signaling; this effect could be further enhanced when engineered M062R-null MYXV was used.
Cisplatin treatment can also affect the tumor environment, including induction of a tumor-specific CD8+ T cell response. We found that pretreatment with replication-competent MYXV followed by cisplatin greatly improved survival, compared with cisplatin alone. Interestingly, treating mice first with cisplatin followed by replicating MYXV did not achieve the same treatment benefit. Even with replicating MYXV, the viral infection was eliminated within 7 days in immunocompetent mice. Thus, it is possible that transient MYXV infection remodels the tumor environment, sensitizing tumor cells to a later cisplatin intervention. It seems that the initial phase of viral replication is crucial to a favorable treatment outcome when the combinatorial and sequential WT MYXV-cisplatin regimen is used. However, intriguingly, use of the replication-defective MYXV, M062R-null MYXV, after cisplatin treatment in this OC dissemination model led to 90% survival in mice and was much more effective than the use of replicating MYXV after cisplatin treatment (60% survival). Cisplatin inhibits DNA replication of MYXV (data not shown); therefore, cisplatin and MYXV cannot be applied at the same time, as was explored with reovirus virotherapy. The lack of statistically significant differences in disease progression between groups treated with cisplatin alone and cisplatin followed by WT MYXV suggests that even 5 days after cessation of cisplatin treatment, the effect of inhibiting a subsequent productive MYXV infection in the tumor environment persists. Accordingly, we speculate that the favorable outcome of cisplatin plus later M062R null MYXV treatment may be unique to this mutant-virus. In human cells, M062R-null MYXV infection activates the anti-neoplastic SAMD9 pathway. It is not known whether infection with M062R-null MYXV in this murine model stimulates a similar pathway that can specifically enhance the outcome of preceding cisplatin treatment.

However, intriguingly, use of the replication-defective MYXV, M062R-null MYXV, after cisplatin treatment in this OC dissemination model led to 90% survival in mice and was much more effective than the use of replicating MYXV after cisplatin treatment (60% survival). Cisplatin inhibits DNA replication of MYXV (data not shown); therefore, cisplatin and MYXV cannot be applied at the same time, as was explored with reovirus virotherapy. The lack of statistically significant differences in disease progression between groups treated with cisplatin alone and cisplatin followed by WT MYXV suggests that even 5 days after cessation of cisplatin treatment, the effect of inhibiting a subsequent productive MYXV infection in the tumor environment persists. Accordingly, we speculate that the favorable outcome of cisplatin plus later M062R null MYXV treatment may be unique to this mutant-virus. In human cells, M062R-null MYXV infection activates the anti-neoplastic SAMD9 pathway. It is not known whether infection with M062R-null MYXV in this murine model stimulates a similar pathway that can specifically enhance the outcome of preceding cisplatin treatment.

In human OC ascites-associated CD14+ cells, M062R-null MYXV effectively suppresses STAT3 phosphorylation (Figure 4B) and AKT (data not shown) and reduces phosphorylated CREB (data not shown), all important signaling molecules in the maintenance of the M2 state of tumor-associated myeloid cells.

Development of novel treatment approaches for OC patients is urgently needed. We showed that an oncolytic virotherapy candidate, MYXV, could be integrated into and complement an existing chemotherapy regimen to improve the treatment benefit in an immunocompetent pre-clinical model. We are investigating the mechanism of MYXV immunotherapeutic potential in the OC tumor environment, especially the effect on OC ascites-associated CD14+ cells. To the best of our knowledge, this is the first study that investigates the benefit of combining MYXV with cisplatin in the treatment of OC in a syngeneic model in vivo.

**MATERIALS AND METHODS**

**Human Subjects**

Ovarian cancer patients were recruited from patients attending the Women’s Oncology clinic in the Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences (UAMS), under an IRB-approved protocol. Ovarian tumor ascites samples were recovered at the time of surgery.

**Characterization of Patient Samples**

1. Clinical characteristics of patient tumor samples are as follows:

   - **OvCa-2a**, clear cell carcinoma
   - **OvCa-26**, metastatic adenocarcinoma that is moderately differentiated but lacks clear-cut high-grade serous, clear cell, or endometrioid differentiation
   - **OvCa-2a** and **OvCa-26**, both newly established ovarian cancer cell lines. **OvCa-2a** is EpCAM\(^\text{+}\) CD133\(^{\text{hi}}\) A-cadherin\(^{\text{neg}}\) and it has a
stem-like phenotype. OvCa-26 is EpCAMhi, CD133hi E-cadherinlo and also has elements of a stem-like phenotype. Both cell lines express ALDH1. TP53 mutation status is unknown.

(2) Clinical characterization of patient tumor type with which tumor-associated macrophages were purified from ascites are as follows:

OvCa-28, mucinous cystadenocarcinoma

OvCa-37, high-grade serous carcinoma

OvCa-43, high-grade serous carcinoma.

Cell Lines and Viruses

SKOV3, 45 OvCa-26 (primary human OC cells), OvCa-2a (primary human OC cells), and ID8 (courtesy of Katherine Roby, PhD, University of Kansas Medical Center) cells46 were cultured in RPMI1640.
(Meditech, Corning, NY) supplemented with 2 mM L-glutamine (Invitrogen, Carlsbad, CA), 5 × 10⁻⁵ M 2-mercaptoethanol (Thermo Fisher Scientific, Waltham, MA), and 100 μg/mL of penicillin/streptomycin (Invitrogen). MYXV viruses, vMyxGFP-WT and M062R-null MYXV (vMyxM062RKO), have been described previously.⁷ Both viruses were engineered to express GFP driven by a viral synthetic promoter from which GFP is synthesized throughout the course of infection. Viruses are amplified on BSC-40 cells and purified through 36% sucrose gradient as previously described.⁷,¹⁷,⁴⁸ BSC-40 cells were cultured in Dulbecco’s minimal essential medium (Lonza, Basel, Switzerland, and Invitrogen) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA), 2 mM glutamine (Corning, Corning, NY), and 100 μg/mL of penicillin/streptomycin (Invitrogen).

Reagents and Antibodies
Chemotherapy drugs cisplatin (Sigma-Aldrich, St. Louis, MO) and gemcitabine (Sigma-Aldrich) were diluted to appropriate concentrations in growth medium for treatment in vitro and were diluted in PBS for animal treatment. Statick (Selleckchem, Houston, TX) was dissolved in DMSO at 10 mM, and patient ascites-associated monocytes were treated at a concentration of 5 μM before cytokine secretion was tested. The antibodies STAT3 pY705, STAT3 pS727, total STAT3, AKT pS473, and pCREB, as well as the Annexin V Apoptosis Detection Kit APC, are from Affymetrix eBioscience (San Diego, CA).

Colony-Formation Assay and MTT Assay
Colony-formation assay was conducted as previously described.²¹ Briefly, cancer cells were treated with MYXV at an MOI of 50 before they were diluted for seeding in a 10-cm dish. Depending on the cell lines used, after 2–6 weeks of growth, cells were fixed and stained with crystal violet for imaging. Cell viability was measured by MTT assay (Promega, Madison, WI) according to the manufacturer’s protocol.

Combinatorial Treatment Test In Vitro
To calculate IC₅₀ dose for each cell line, we adopted a method similar to what was previously reported.²¹ Briefly, cells were treated with chemotherapy drug at serial diluted doses for 48–72 hr before cell proliferation was measured with MTT assay.

Primary patient ascites-derived tumor cells (OvCa-2a and OvCa-26) were mock-treated or infected with MYXV (replicating WT or defective M062R-null MYXV) at an MOI of 10 for 48 hr before they were cultured for 24 hr in fresh medium without any treatment; cells were then treated with a second treatment (chemotherapy or virus) for another 48 hr before cell viability was measured with MTT assay (Promega).

Human Healthy CD14⁺ Monocytes and OC Patient Tumor-Associated CD14⁺ Monocytes
Human CD14⁺ monocytes are from healthy female donors (Lonza). OC tumor-associated CD14⁺ monocytes were purified from patient ascites as described previously.²⁸ Briefly, primary ovarian tumor ascites CD14⁺ cells were separated magnetically using commercially available columns and anti-CD14 conjugated microbeads (Miltenyi Biotec, Auburn, CA), according to the manufacturer’s instructions. The purity of recovered ascites CD14⁺ cells was typically 95%–98%.

Flow Cytometry, ELISA, and Multiplex Array
After appropriate treatments, cells were fixed and permeabilized with fixation/permeabilization concentrate (Affymetrix eBioscience) and stained according to the manufacturer’s instructions with antibodies recognizing intracellular signaling phosphoproteins. The mouse IFNγ ELISA and ProcartaPlex human inflammation panel (20plex) (Affymetrix eBioscience) were performed according to manufacturer’s instructions. A customized multiplex array (Millipore, Billerica, MA) was used to characterize Statick-treated patient-ascites monocytes. To examine IFNγ secretion in splenocytes to tumor antigen stimulation, mouse splenocytes were harvested and treated with ACK lysing buffer (Thermo Fisher Scientific) at 1:1 volume ratio for 5 min at room temperature before cells were pelleted. Approximately 10 million cells per mouse were either mock treated or stimulated with ID8 cell lysate (technical replicates in duplicate). At 1 day and 3 days post-stimulation, a sample of supernatant was taken per well and stored at −80°C for ELISA (eBioscience). These splenocytes continued to be cultured, and at day 6, media were replaced to contain ID8 tumor lysate for the second round of stimulation. At days 7 and 10, samples of supernatant were again taken per well for ELISA. To prepare ID8 tumor cell lysate as a crude tumor antigen preparation, we resuspended one million ID8 cells in 1 mL of medium for 3 rounds of freeze-thaw cycle followed by sonication; 125 μL of tumor cell lysate was used to stimulate 10 million splenocytes.

Murine Model of OC Dissemination and Treatments
The animal studies were approved by the IACUC at the University of Arkansas for Medical Sciences (UAMS). Cisplatin was administered at 3 mg/kg every 3 days as described previously.⁴⁹ In a regimen modified from those described previously,¹³,³⁰ gemcitabine was administered at 50 mg/kg every other day for a total four treatments. Virotherapy was carried out every other day for a total of four or five intraperitoneal (i.p.) injections as described previously.²¹

To test the therapeutic effect of combined virus and chemotherapy treatment, treatment started 7 days after i.p. injection of a dose of 6 × 10⁶ tumor cells/mouse. Injecting fewer cells of this ID8 clone (e.g., 1 × 10⁶ or 3 × 10⁶ cells) failed to provide the same disease progression and survival outcome as shown in this study (e.g., Figure S2). For combinatorial treatment of virus followed by cisplatin, four i.p. injections of 1 × 10⁶ plaque-forming units (PFUs)/mouse every other day were carried out, and cisplatin treatment was begun 5 days after the last injection of virus as described above. For combination treatment of cisplatin first followed by virus, cisplatin treatment was carried out as described above with a 5-day interval before the virus treatment (five injections every other day). As a control, cisplatin treatment was tested at either 7 days (early) or 16 days (late) post-injection of tumor cells. To test single-agent virotherapy, cisplatin, or gemcitabine treatment, treatments were initiated at 16 days post-tumor-injection.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this article online at http://dx.doi.org/10.1016/j.omto.2017.08.002.

AUTHOR CONTRIBUTIONS
Investigation: B.N., J. Liem, M.C., J. Liu; Methodology, Funding Acquisition, and Writing – Review and Editing: M.C., J. Liu; Conceptualization, Supervision, Visualization, and Writing – Original Draft: J. Liu.

CONFLICTS OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
This work was supported in part by NIH K22-A99184 and P20GM103625, the Cookie Laughlin Award from Rivkin Center for Ovarian Cancer, and a start-up fund by the UAMS Department of Microbiology and Immunology to J. Liu. This work was supported in part by P50 CA-136393 (Mayo Clinic SPORE in Ovarian Cancer), of Microbiology and Immunology to J. Liu. This work was supported in part by P50 CA-136393 (Mayo Clinic SPORE in Ovarian Cancer, and a start-up fund by the UAMS Department of Microbiology and Immunology to J. Liu. This work was supported in part by P50 CA-136393 (Mayo Clinic SPORE in Ovarian Cancer, and a start-up fund by the UAMS Department of Microbiology and Immunology to J. Liu. This work was supported in part by P50 CA-136393 (Mayo Clinic SPORE in Ovarian Cancer, and a start-up fund by the UAMS Department of Microbiology and Immunology to J. Liu. This work was supported in part by P50 CA-136393 (Mayo Clinic SPORE in Ovarian Cancer, and a start-up fund by the UAMS Department of Microbiology and Immunology to J. Liu. This work was supported in part by P50 CA-136393 (Mayo Clinic SPORE in Ovarian Cancer, and a start-up fund by the UAMS Department of Microbiology and Immunology to J. Liu.

REFERENCES
1. Bukowski, R.M., Ozols, R.F., and Markman, M. (2007). The management of recurrent ovarian cancer. Semin. Oncol. 34 (Suppl 2), S1–S15.
2. Ozols, R.F. (2006). Challenges for chemotherapy in ovarian cancer. Ann. Oncol. 17 (Suppl 5), v181–v187.
3. Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Masoodri, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M.N., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213.
4. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949.
5. Cannon, M.J., Ghosh, D., and Gujja, S. (2015). Signaling circuits and regulation of immune suppression by ovarian tumor-associated macrophages. Vaccines (Basel) 3, 448–466.
6. Goyne, H.E., and Cannon, M.J. (2013). Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer. Front. Immunol. 4, 382.
7. Fukuhara, H., Ino, Y., and Todo, T. (2016). Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 107, 1373–1379.
8. Kaufman, H.L., Kohlpp, F.I., and Zlotta, A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662.
9. Arulananandam, R., Ratenchuk, C., Varetto, O., Zakaria, G., Garcia, V., Forbes, N.E., Davis, C., Krishnan, R., Karmacharya, R., Cox, J., et al. (2015). Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat. Commun. 6, 6410.
10. Bibl, A.E., Spliopoulou, P., and Evans, T.R. (2016). Virotherapy: cancer gene therapy at last? [version 1; referees: 2 approved]. F1000Res. 5, 2105.
11. Woller, N., Gürlevik, E., Ureche, C.L., Schumacher, A., and Kühnel, F. (2014). Oncolytic viruses as anticancer vaccines. Front. Oncol. 4, 188.
12. Thorne, S.H., Liang, W., Sampath, P., Schmidt, T., Sikorski, R., Beilhack, A., and Contag, C.H. (2010). Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol. Ther. 18, 1698–1705.
13. Keller, B.A., and Bell, J.C. (2016). Oncolytic viruses-immunotherapeutics on the rise. J. Mol. Med. (Berl.) 94, 979–991.
14. Wernier, S.T., Liu, J., and McFadden, G. (2012). Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. Curr. Pharm. Biotechnol. 13, 1817–1833.
15. Simpson, G.R., Relph, K., Harrington, K., Melcher, A., and Pandha, H. (2016). Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virotro. 5, 1–13.
16. Chan, W.M., Rahman, M.M., and McFadden, G. (2013). Oncolytic myxoma virus: the path to clinic. Vaccine 31, 4252–4258.
17. Wang, F., Gao, X., Barrett, J.W., Shao, Q., Bartee, E., Mohamed, M.R., Rahman, M., Werden, S., Irvine, T., Cao, J., et al. (2008). RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog. 4, e1000099.
18. Wang, F., Barrett, J.W., Ma, Y., Dekaban, G.A., and McFadden, G. (2009). Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized. J. Virol. 83, 5928–5932.
19. Correa, R.J., Komar, M., Tong, J.G., Sivapragasam, M., Rahman, M.M., McFadden, G., Dimatta, G.E., and Shepherd, T.G. (2012). Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecol. Oncol. 125, 441–456.
20. Tong, J.G., Ramos Valdes, Y., Barrett, J.W., Bell, J.C., Stojil, D., McFadden, G., McCart, J.A., DiMattia, G.E., and Shepherd, T.G. (2015). Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis. Mol. Ther. Oncolytics 2, 15013.
21. Wernier, S.T., Liu, J., Li, S., Rahman, M.M., Mon, A., and McFadden, G. (2012). Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol. Ther 20, 759–768.
22. Moo-Young, T.A., Larson, J.W., Belt, B.A., Tan, M.C., Hawkins, W.G., Eberlein, T.J., Goedegebuure, P.S., and Linehan, D.C. (2009). Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreatic cancer. J. Immunother. 32, 12–21.
23. Tan, M.C., Goedegebuure, P.S., Belt, B.A., Flaherty, B., Sankpal, N., Gillanders, W.E., Eberlein, T.J., Huei, C.S., and Linehan, D.C. (2009). Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 182, 1746–1755.
24. Dasari, S., and Tchoungwou, P.B. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364–378.
25. Tseng, C.W., Hung, C.F., Alvarez, R.D., Trimbile, C., Huh, W.K., Kim, D., Chuang, C.M., Lin, C.T., Tsai, Y.C., He, L., et al. (2008). Pretreatment with cisplatin enhances E7-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. Clin. Cancer Res. 14, 3185–3192.
26. Pandha, H.S., Heinemann, L., Simpson, G.R., Melcher, A., Prestwich, R., Errington, F., Coffey, M., Harrington, K.J., and Morgan, R. (2009). Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin. Cancer Res. 15, 6158–6166.
27. Moehler, M., Sieben, M., Roth, S., Springfug Cell, T., Leuchs, B., Zeidler, M., Dinsart, C., Rommelereae, J., and Galle, P.R. (2011). Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1: BMC Cancer 11, 464.
28. Wilke, C.M., Kryczek, I., and Zou, W. (2011). Antigen-presenting cell (APC) subsets in ovarian cancer. Int. Rev. Immunol. 30, 120–126.
